Disclosure Of Entity's Operating Segments [Text Block]

Innate Pharma - Filing #2821023

Concept As at
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2019-01-01 to
2019-12-31
2019-01-01 to
2019-12-31
As at
2019-12-31
Disclosure of entity's operating segments [text block]
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
70 451 EUR
85 814 EUR
Tax expense (income)
EUR
EUR
Profit (loss) before tax
63 984 EUR
20 759 EUR
Profit (loss)
63 984 EUR
63 984 EUR
20 759 EUR
20 759 EUR
Assets
307 423 EUR
401 361 EUR
Cash flows from (used in) operating activities
51 767 EUR
34 924 EUR
Cash flows from (used in) investing activities
13 370 EUR
62 121 EUR
Cash flows from (used in) financing activities
1 177 EUR
77 765 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.